Alzamend Neuro Inc (ALZN) Stock Analysis & Investment Frameworks
Alzamend Neuro Inc (ALZN) stock analysis on Invetso. Review Alzamend Neuro Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Alzamend Neuro Inc Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Alzamend Neuro Inc Key Financial Metrics
- Market Cap: $6.80M
- Revenue: $N/A
- ROE: -277.88%
- ROIC: -156.69%
- Dividend Yield: N/A
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro Inc Investment Frameworks
Invetso analyzes Alzamend Neuro Inc (ALZN) across the following frameworks:
- Alzamend Neuro Inc 10Y Growth Potential
- Alzamend Neuro Inc Scenario Analysis
- Alzamend Neuro Inc Risks & Opportunities
- Alzamend Neuro Inc Economic Moat
- Alzamend Neuro Inc Business Model
- Alzamend Neuro Inc Management
- Alzamend Neuro Inc SWOT Analysis
- Alzamend Neuro Inc Porter's 5 Forces
- Alzamend Neuro Inc PESTLE Analysis
- Alzamend Neuro Inc ESG Analysis